FDA AdComm meeting over Novartis' Serelaxin

|About: Novartis AG (NVS)|By:, SA News Editor

An FDA advisory committee is meeting to discuss whether to approve Novartis' (NVS) Serelaxin treatment for acute heart failure.

On Tuesday, FDA staff recommended that the agency not approve Serelaxin.

You can watch the AdComm here.